Academic literature on the topic 'Hepatitis B cor'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Hepatitis B cor.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Hepatitis B cor"
Maria, Rafael Carvalho de, Joseneide Teixeira Câmara, Maria Edileuza Soares Moura, Felipe Santana e. Silva, and Josemeire da Costa Ximenes. "Analysis of space and epidemiological distribution of hepatitis b and c cases in municipaly maranhão / Análise da distribuição espacial e epidemiológica dos casos de hepatite b e c em município maranhense." Revista de Pesquisa Cuidado é Fundamental Online 13 (September 22, 2021): 1421–27. http://dx.doi.org/10.9789/2175-5361.rpcfo.v13.9702.
Full textPolish, L. B., M. Gallagher, H. A. Fields, and S. C. Hadler. "Delta hepatitis: molecular biology and clinical and epidemiological features." Clinical Microbiology Reviews 6, no. 3 (July 1993): 211–29. http://dx.doi.org/10.1128/cmr.6.3.211.
Full textToy, Mehlika, Samuel So, and David W. Hutton. "Hepatitis B cure." Current Opinion in HIV and AIDS 15, no. 3 (May 2020): 208–12. http://dx.doi.org/10.1097/coh.0000000000000617.
Full textValsamakis, Alexandra. "Molecular Testing in the Diagnosis and Management of Chronic Hepatitis B." Clinical Microbiology Reviews 20, no. 3 (July 2007): 426–39. http://dx.doi.org/10.1128/cmr.00009-07.
Full textMahoney, Francis J. "Update on Diagnosis, Management, and Prevention of Hepatitis B Virus Infection." Clinical Microbiology Reviews 12, no. 2 (April 1, 1999): 351–66. http://dx.doi.org/10.1128/cmr.12.2.351.
Full textFeitelson, M. "Hepatitis B virus infection and primary hepatocellular carcinoma." Clinical Microbiology Reviews 5, no. 3 (July 1992): 275–301. http://dx.doi.org/10.1128/cmr.5.3.275.
Full textAudsley, Jennifer, and Joe Sasadeusz. "Challenges and opportunities for hepatitis B cure in the setting of HIV--hepatitis B virus co-infection." Current Opinion in HIV and AIDS 15, no. 3 (May 2020): 193–99. http://dx.doi.org/10.1097/coh.0000000000000624.
Full textSugarman, Jeremy. "Ethics of HIV and hepatitis B cure research." Current Opinion in HIV and AIDS 15, no. 3 (May 2020): 180–84. http://dx.doi.org/10.1097/coh.0000000000000618.
Full textZhou, Xiaojing, Hongfei Wei, Peng Sun, Xiuli Wu, Min Wan, Peng Zhang, Sheng Guo, Tiesuo Zhao, Yongli Yu, and Liying Wang. "Recombinant Hepatitis B Virus Surface Antigen Formulated with B-Type CpG Oligodeoxynucleotide Induces Therapeutic Immunity Against Hepatitis B Virus Surface Antigen-Expressing Liver Cancer Cells in Mice." Cancer Biotherapy and Radiopharmaceuticals 27, no. 4 (May 2012): 234–42. http://dx.doi.org/10.1089/cbr.2011.1127.
Full textMaini, Mala K., and Dimitra Peppa. "Shared immunotherapeutic approaches in HIV and hepatitis B virus." Current Opinion in HIV and AIDS 15, no. 3 (May 2020): 157–64. http://dx.doi.org/10.1097/coh.0000000000000621.
Full textDissertations / Theses on the topic "Hepatitis B cor"
Alencar, Regiane Saraiva de Souza Melo. "Ocorrência da infecção oculta pelo vírus da hepatite B (VHB) em pacientes com cirrose hepática pelo vírus da hepatite C (VHC) com ou sem carcinoma hepatocelular (CHC)." Universidade de São Paulo, 2006. http://www.teses.usp.br/teses/disponiveis/5/5147/tde-16102014-103147/.
Full textThis study evaluated serum and liver tissue samples from 50 patients with liver cirrhosis due to hepatitis C virus (HVC) that underwent liver transplant at the Hospital das Clínicas - University of São Paulo School of Medicine during the period of 1993 to 2004, divided into two groups: Group 1 (33 cirrhotic patients due to HCV) and Group 2 (17 cirrhotic patients due to HCV with hepatocellular carcinoma - HCC). Our aim was to study the occurrence of occult HBV0 infection in cirrhotic patients due to HCV with or without HCC through the molecular study of HBV DNA in the serum, tumoral liver tissue and non tumoral liver tissue by the polymerase chain reaction (PCR) techniques using in house and real time PCR. All the patients were HBsAg negative, having previous serum samples frozen at -20ºC and liver tissue explanted in paraffin, without presenting concomitant cholestatic, metabolic and autoimmune liver diseases. The following variables were collected: gender, age, biochemical and coagulation laboratory tests and HBV serology (HBsAg, anti-HBc total, anti-HBs). Among the clinical data, ascites and encephalopathy were collected for the Child and MELD prognostic indexes. In the explanted liver tissue the Ishak\'s Score, The Brazilian Society of Pathology and Hepatology Classification for chronic hepatitis, and Edmondson and Steiner Classification for HCC were applied in the liver tissue. All samples with or without tumoral liver tissue and serum were negative for HBV DNA using in house PCR technique. By the real time PCR technique only one case from Group 2 was HBV DNA positive in serum (male, 66, isolated anti-HBc total positive and HCC). In the tumoral and non-tumoral liver tissues there were two indeterminated HBV DNA cases among Group 2 patients. All samples for Group 1 patients were negative for HBV DNA using both techniques. In conclusion, our study has shown the extremely low occult hepatitis B virus infection among the HCV cirrhotic patients with or without HCC, maybe due to the low HBV past infection among the Southeastern Brazilian population
Silva, Edvaldo Ferreira da. "Prevalência de marcadores sorológicos das hepatites A e B em pacientes com hepatite C crônica atendidos no ambulatório de hepatites do serviço de Gastroenterologia Clínica do Hospital das Clínicas da Faculdade de Medicina da Universidade." Universidade de São Paulo, 2014. http://www.teses.usp.br/teses/disponiveis/5/5168/tde-04022015-153903/.
Full textBackground and Aims: Patients with chronic HCV and superinfection by hepatitis A virus (HAV) or hepatitis B virus (HBV) have higher morbidity and mortality when compared with those without HCV. For this reason, HAV and HBV active immunization has become mandatory in this population and hence their serological markers must be determined. The aim of this study was to evaluate the prevalence of serological markers of HAV and HBV infection in patients with chronic HCV. Methods: 1.000 chronic HCV infected patients at the University of Sao Paulo School of Medicine outpatient Liver Clinic were evaluated for the prevalence of serological markers of HAV and HBV infection. Results: Anti-HAV IgG was positive in 923 of 1000 patients (92.3%). When stratified by age, the anti-HAV IgG was found in 61% of patients between 20-29 years, 70% between 30-39 years, 85% between 40-49 years, 94% between 50-59 years, and 99% over 60 years of age. Anti-HBc IgG was positive in 244 patients (24%). Stratified by age, anti-HBc IgG was found in 4.3% of patients between 20-29 years, 17% between 30-39 years, 21% between 40 -49 years, 24% between 50-59 years, and 28% of patients over 60 years of age. Of the 244 anti-HBc IgG positive patients, 0.8% were also HBsAg positive, 8.5% were anti-HBc IgG isolated and 16% were also anti-HBs positive. Conclusions: The prevalence of anti-HAV IgG was similar to the general population in the city of São Paulo. However, anti-HBc IgG was higher in our chronic HCV patients, when compared historically to the general population of western countries, suggesting similar risk factors for HBV and HCV acquisition, so emphasizing the importance of immunization programs in this population. Keywords: Hepatitis C, Chronic; Hepatitis C; Hepacivirus, Prevalence; Hepatitis A; Hepatitis B Título: Prevalência de Marcadores Sorológicos das Hepatites A e B em Pacientes com Hepatite C Crônica atendidos no Ambulatório de Hepatites do Serviço de Gastroenterologia Clínica do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo - HCFMUSP Background and Aims: Patients with chronic HCV and superinfection by hepatitis A virus (HAV) or hepatitis B virus (HBV) have higher morbidity and mortality when compared with those without HCV. For this reason, HAV and HBV active immunization has become mandatory in this population and hence their serological markers must be determined. The aim of this study was to evaluate the prevalence of serological markers of HAV and HBV infection in patients with chronic HCV. Methods: 1.000 chronic HCV infected patients at the University of Sao Paulo School of Medicine outpatient Liver Clinic were evaluated for the prevalence of serological markers of HAV and HBV infection. Results: Anti-HAV IgG was positive in 923 of 1000 patients (92.3%). When stratified by age, the anti-HAV IgG was found in 61% of patients between 20-29 years, 70% between 30-39 years, 85% between 40-49 years, 94% between 50-59 years, and 99% over 60 years of age. Anti-HBc IgG was positive in 244 patients (24%). Stratified by age, anti-HBc IgG was found in 4.3% of patients between 20-29 years, 17% between 30-39 years, 21% between 40 -49 years, 24% between 50-59 years, and 28% of patients over 60 years of age. Of the 244 anti-HBc IgG positive patients, 0.8% were also HBsAg positive, 8.5% were anti-HBc IgG isolated and 16% were also anti-HBs positive. Conclusions: The prevalence of anti-HAV IgG was similar to the general population in the city of São Paulo. However, anti-HBc IgG was higher in our chronic HCV patients, when compared historically to the general population of western countries, suggesting similar risk factors for HBV and HCV acquisition, so emphasizing the importance of immunization programs in this population
Pacher, Bianca Messenberg. "Hepatites causadas pelos vírus B e C entre a população surda de Ribeirão Preto." Universidade de São Paulo, 2014. http://www.teses.usp.br/teses/disponiveis/17/17139/tde-15082014-110519/.
Full textHepatitis B and C are still an important public health problem in the world, with chronic carriers estimated at around 350 million and 170 million, respectively, causing a large number of people to be at risk of chronic forms and progression to liver cirrhosis and hepatocellular carcinoma. Among the most well-known risk factors for hepatitis B are blood and derivatives transfusions, contact with blood and/or secretions by unprotected sex, sharing needles and/or syringes in injectable drug use, tattooing and piercing with contaminated material. Hepatitis C is transmitted primarily by parenteral way and its prevention is similar to hepatitis B. Several risk factors for both seem to be present in the deaf population, which is historically marginalized in terms of access to health information and services and on which there are no references to research on viral hepatitis. This work aimed to estimate the prevalence of positive serology for hepatitis B and C and to investigate possible risk factors among the deaf population of Ribeirão Preto. An explanatory DVD about the features and risks of hepatitis B and C was presented to them in Brazilian Sign Language. Eighty eight deaf agreed to participate, signed a free and informed consent form and were included in the investigation. A standardized questionnaire was applied and a sample of blood was collected. Immunoenzymatic tests for detection of HBsAg, anti-HBS, anti-HBC and anti-HCV markers were carried out at the Serum Laboratory of the University Hospital of the Ribeirão Preto Medical School, University of São Paulo. The serological analysis revealed the presence of current or previous infection by hepatitis B in seven participants, representing 8% of total prevalence of markers (CI95%: 2,3 13,7). When analyzing the possible risk factors, it was found association between infection and the variables being born in another State other than São Paulo and past history of imprisonment. No positive samples for hepatitis C were found. The participants showed great ignorance about basic aspects related to the transmission of viral hepatitis, indicating need for public health policies directed to this population that takes into account their linguistic and cultural singularities.
Arrelias, Clarissa Cordeiro Alves. "Prevalência de marcadores sorológicos para hepatite B e C e potenciais fatores de risco em pacientes com diabetes mellitus de uma Unidade Básica Distrital de Saúde, Ribeirão Preto-SP, 2014." Universidade de São Paulo, 2017. http://www.teses.usp.br/teses/disponiveis/22/22132/tde-25012018-110725/.
Full textA cross-sectional observational study aimed at characterizing patients with diabetes mellitus according to demographic and clinical variables; to estimate the prevalence of hepatitis B and C virus infection and vaccine coverage in patients with diabetes mellitus and to identify potential related risk factors. The convenience sample consisted of 255 patients with diabetes mellitus who attended the medical consultation in the outpatient clinics of Endocrinology and Integrated Medical Clinic of the District Health Unit of Ribeirão Preto-SP, from July to December 2014. The selected demographic variables the use of insulin, capillary blood glucose monitoring, history of medical, surgical, diagnostic and therapeutic interventions and risky situations and behaviors for hepatitis B and C. The serological markers investigated were HBsAg, Anti -HBc IgG, Anti-HBc IgM, Anti-HBs and Anti-HCV. Three or more doses of the registered hepatitis B vaccine were considered complete vaccination. To collect data, a questionnaire was used, consulting the vaccination record of the Health Management Computerized System of Health of the Municipal Health Department and venous blood collection. The data were presented by means of descriptive statistics. Univariate analysis of possible associations between demographic and clinical variables and outcomes of hepatitis B and C virus infection and vaccine coverage against hepatitis B was determined by the Pearson-corrected chi-square test or Wilcoxon\'s exact Fisher\'s test for Unpaired samples. For the multivariate analysis, a logistic regression model was constructed in which variables that exhibited p <0.2 were included in the univariate analysis. Values of \'p\' below 5% were considered significant. The results showed that 16.8% of the patients presented total anti-HBc marker reagent, 8.2% Anti-HBs alone and 75% were non-reactive for all hepatitis B markers. No case of HBsAg reagent was found in the sample studied. Regarding hepatitis C virus infection, 3.3% of the patients presented anti-HCV marker reagent. The prevalence of hepatitis B virus (Anti-HBc reagent) in patients with diabetes mellitus was 16.8% higher than the national level and was directly associated with the time of diabetes mellitus. The prevalence of hepatitis C virus infection (Anti-HCV reagent) was 3.3%, higher than the national level, but had no association with the demographic and clinical variables investigated. Hepatitis B vaccination coverage was shown to be low (15%) in patients with diabetes mellitus evidencing their vulnerability to this serious and potentially fatal disease. Higher schooling and work in the health area were associated with better vaccine coverage. These results provide important insights for the evaluation of nurses\' clinical practice in primary health care for care related to vaccination coverage for people with diabetes mellitus. Thus, efforts must be made by health professionals and services to meet the challenge of providing ample vaccination coverage to this population, ensuring the prevention of hepatitis B and C virus infection
Rosa, Mariana Nogueira de Paula. "Avaliação da resposta sorologica a imunização contra hepatites A e B em pacientes com hipertensão portal." [s.n.], 2007. http://repositorio.unicamp.br/jspui/handle/REPOSIP/313697.
Full textDissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Ciencias Medicas
Made available in DSpace on 2018-08-08T20:45:32Z (GMT). No. of bitstreams: 1 Rosa_MarianaNogueiradePaula_M.pdf: 1246789 bytes, checksum: 4d75875746a0c9dddc300904721c7941 (MD5) Previous issue date: 2007
Resumo: Anualmente ocorrem, no Brasil, cerca de 130 casos novos de hepatite A por 100000 habitantes e o país é considerado área de risco para a doença. A soroprevalência vai aumentando com a idade. Estima-se que, aproximadamente, 15% da população já entrou em contato com o vírus da hepatite B e que 1% apresenta doença crônica. A resposta à vacina da hepatite A está diminuída em pacientes com doença hepática crônica descompensada e a taxa de resposta à vacinação rotineira contra o vírus B em indivíduos imunossuprimidos é menor que em indivíduos saudáveis. A hipertensão portal pode determinar esplenomegalia e levar ao hiperesplenismo com redução nos números absoluto e percentual de células T, podendo determinar, dessa forma, uma diminuição da resposta à vacinação. Este estudo tem por objetivo avaliar a resposta à vacinação contra as hepatites A e B, em pacientes com hipertensão portal secundária a hepatopatia crônica ou trombose de veia porta. Foram avaliados 36 pacientes, de 2 a IS anos, com hipertensão portal, atendidos no Ambulatório de Hepatologia Pediátrica do Hospital de Clínicas da Universidade Estadual de Campinas, no período de 1994 a 2006. As sorologias para hepatites A e B foram realizadas nos pacientes já vacinados e nos pacientes que nunca receberam as vacinas. Os pacientes não vacinados receberam as vacinas durante o período do estudo. Os pacientes com títulos negativos de anti-HBs foram submetidos a dose de reforço e a sorologia foi repetida após o reforço. Avaliações hematimétricas dos pacientes foram realizadas, juntamente com as sorologias, para avaliar as alterações decorrentes da imunossupressão secundária à doença de base e ao hiperesplenismo. Dezenove pacientes receberam a vacina contra hepatite A e todos apresentaram resposta à vacina. Todos os pacientes receberam 3 doses da vacina contra hepatite B e vinte e sete pacientes (75%) apresentavam anti-HBs positivo. Nove pacientes foram submetidos à dose de reforço e nove apresentaram anti-HBs positivo após o reforço. A análise estatística realizada, por meio do teste de Mann-Whitney, para a comparação dos pacientes anti-HBs positivo e anti-HBs negativo com relação às variáveis idade, leucócitos, linfócitos e tempo entre a vacinação e a realização da sorologia não demonstrou diferença estatisticamente significativa. Os resultados permitem concluir que: 1. a vacina contra hepatite A apresentou 100% de resposta em pacientes com hipertensão portal e 2. a vacina contra hepatite B parece conferir proteção e induzir à resposta anamnéstica nesses pacientes.
Abstract: Anually, about 130 new cases of hepatitis A per 100000 inhabitants occur in Brazil, and the country is considered a risk area for the disease. About 15% of brazilian population has been in contact with hepatitis B virus and 1% has chronic disease. Hepatitis A vaccine response is diminished in patients with decompensated chronic disease, and response to routine vaccination against VHB in imunossupressed subjects is lower than in healthy subjects. Portal hypertension lead to hypersplenysm and decrease of absolute and percentual numbers of T cells, and a lower response to vaccination could occur. The purpose of this study was to evaluate response to hepatitis A e B vaccination in patients with portal hypertension secondary to chronic liver disease or portal vein thrombosis. Thirty six patients (2 to 18 years) with portal hypertension were evaluated, assisted at Pediatric Hepatology Service of the Hospital das Clínicas da Universidade Estadual de Campinas, from 1994 to 2006. Hepatitis A and B serologies were done in all patients. Patients who weren't vaccinated received vaccines during the study period and patients with negative anti-HBs received a booster dose, and serology was repeated after booster. Hematimetric evaluation of patients was done as the same time as serologies, for evaluation of immunosupression secondary to chronic liver disease and to hypersplenism. Nineteen patients received hepatitis A vaccine and all presented positive anti-VHA. All patients received hepatitis B vaccine, and 27 patients (75%) presented positive anti-HBs. Nine patients received a booster dose, and nine presented positive anti-HBs after booster. Statistic analysis was done by Mann-Whitney test to compare positive anti-HBs group and negative anti-HBs group. Variables age, leucocytes, limphocytes and time between vaccination and serology were analyzed, and there wasn't statistically significative diference between the groups. These results demonstrate that vaccine against hepatitis A presented a 100% response in patients with portal hypertension, and vaccine against hepatitis B seems to confer protection and to induce an anamnestic response in these patients.
Mestrado
Pediatria
Mestre em Saude da Criança e do Adolescente
Lima, Livia de Souza Botelho. "Avaliação de fatores virológicos associados ao desenvolvimento de carcinoma hepatocelular (CHC) em pacientes com hepatite B crônica." Universidade de São Paulo, 2016. http://www.teses.usp.br/teses/disponiveis/5/5168/tde-20052016-150206/.
Full textThe aim of this study was to evaluate viral factors associated with the progression to hepatocellular carcinoma (HCC) in patients with chronic hepatitis B. For this goal, we characterized HBV subgenotypes, investigated the occurrence of mutations in pre-core/core genes associated with progression to HCC, characterized HBV strains through phylogenetic analyzes and evaluated risk factors associated with HCC. Were included 119 serum samples from patients with chronic HBV infection that were classified in 2 groups: 60 patients with confirmed HCC diagnosis (group 1) and 59 patients with advanced hepatitis B liver disease without the detection of nodular liver lesions and without HCC (group 2). Data about the age, sex and geographic precedence were obtained from medical records. The patients also answered a questionnaire on risk factors for developing HCC. Biochemical, serological and viral load testing were performed in all samples. Moreover, S/polymerase and precore /core regions of HBV DNA were amplified by nested PCR and sequenced by Sanger method. Sequences were analyzed to identify HBV genotypes and subgenotypes and to detect mutations in the precore/core gene. Patient\'s age and sex did not differ between the two groups. Most of the patients came from the Southeast region, followed by the Northeast region; and six patients were from other countries. Based on the patient\'s surname, they were evaluated concerning Eastern ethnicity, which was similar in the 2 groups. Most of the patients included in this study were HBeAg negative and showed viral load bellow 2,000 IU/mL. Concerning the biochemistry assays, statistically significant differences in serum levels of AFP (p = 0.0013), AP (p = 0.0003) and GGT (p = 0.005) were found. Among the risk factors analyzed in this study, peanut consumption was the only one statistically significant (p = 0.003). The S/pol region was successfully amplified and sequenced in 58 samples (28 from Group 1 and 30 from Group 2). Among the 58 samples analyzed, 4 genotypes and 8 subgenotypes were identified, subgenotype A1 was the most frequent in both groups and there was no statistically significant difference in the distribution of them between the two groups. In the phylogenetic tree topology built with HBV sequences isolated from patients included in this study and sequences available in GenBank, it was not observed any clustering associated with the clinical profile of the patients (with or without HCC). Sequences of good quality from pre-core/core region were obtained from 44 samples, 20 from group 1 and 24 from group 2. These sequences were analyzed and several mutations were found among which stood out with statistical significance: T1768A (p = 0.006) C1766T + T1768A (p = 0.043) and G1888H (p = 0.05). In addition to the comparative analysis, the changes were subjected to a simple logistic regression analysis which found that the chance of a patient in group 2 developed HCC increases 14.7 times in the presence of HBV infection strains with the T1768A mutation, while infection with HBV strains harboring the mutation G1888H reduces this chance by 2.5 times
Oba, Paula Franco. "Resposta imune à vacina contra hepatite B com suplementação de beta-glucanas." Botucatu, 2020. http://hdl.handle.net/11449/192398.
Full textResumo: A infecção crônica pelo vírus da hepatite B (VHB) é a principal causa de cronificação da hepatite, cirrose hepática e carcinoma hepatocelular em humanos. A vacinação contra hepatite B é essencial a saúde da população, sendo a medida de menor custo e maior eficiência para controlar o vírus. A vacina desencadeia resposta imune com produção de anticorpos contra o antígeno de superfície do VHB (anti-HBs), contudo, alguns indivíduos não desenvolvem imunidade efetiva, havendo necessidade de doses adicionais. Assim, estimular a resposta imune nos indivíduos já vacinados, porém pouco respondedores ou não respondedores previamente, poderia contribuir para o aumento da produção de anticorpos e persistência dos mesmos ao longo do tempo. Considerando o potencial imunomodulador de β-glucanas, inclusive no aumento da ativação de células T e B em resposta a antígenos, propôs-se neste estudo avaliar a influência do uso de β-glucanas como suplemento alimentar em indivíduos com imunidade não efetiva pós-vacina, que necessitassem de dose booster. Foram incluídos 46 doadores de sangue do Hemocentro de Botucatu, com idade entre 18 anos e 25 anos completos, do sexo masculino, vacinados com três doses para hepatite B na primeira infância. Aqueles que apresentaram anti-HBs<10UI/L foram considerados não imunes, sendo mantidos no estudo (n=31) e divididos em dois grupos de forma aleatória. Ambos os grupos receberam booster da vacina, sendo um grupo suplementado via oral com cápsulas de amido (n=11; pl... (Resumo completo, clicar acesso eletrônico abaixo)
Abstract: Chronic hepatitis B virus (HBV) infection is the main cause of hepatitis chronification, liver cirrhosis and hepatocellular carcinoma in humans. Vaccination against hepatitis B is essential to the health of the population, being the least costly and most efficient measure to control the virus. The vaccine triggers an immune response with the production of antibodies against HBV surface antigen (Anti-HBs), however, some individuals do not develop effective immunity, requiring additional doses. Thus, stimulating the immune response in individuals who have already been vaccinated, but with little or no previous response, could contribute to increased antibody production and persistence over time. Considering the immunomodulatory potential of β-glucans, including the increased activation of T and B cells in response to antigens, it was proposed in this study to evaluate the influence of the use of βglucans as a food supplement in individuals with post-vaccine ineffective immunity , who needed a booster dose. 46 blood donors from the Hemocenter of Botucatu, aged between 18 and 25 years old, male, who received three doses of hepatitis B vaccine in childhood were included. Those who had anti-HBs <10 IU / L were considered non-immune, being maintained in the study (n = 31) and randomly divided into two groups. Both groups received a vaccine booster, one group supplemented orally with starch capsules (n = 11; placebo - 500mg / day), and the other with β-glucans (n = 20; 500mg / day) f... (Complete abstract click electronic access below)
Mestre
Filgueira, Fabiana Ariston. "Estudo de títulos protetores para o vírus de hepatite B após esquema vacinal de três doses e \"booster\" em crianças com HIV." Universidade de São Paulo, 2008. http://www.teses.usp.br/teses/disponiveis/5/5141/tde-24112008-103206/.
Full textINTRODUCTION: Hepatitis B is a disease for which there is no effective healing treatment and which can bring about such severe consequences as cirrhosis and hepatocellular carcinoma . According to the World Health Organization (WHO), more than two billion people are currently infected with the hepatitis B virus and the disease is responsible for half a million to one million deaths a year worldwide. Coinfection with hepatitis B virus is common in HIV-infected patients, since both viruses share similar transmission means. Within this context, adequate immunization of HIV-infected people is crucial for hepatitis B prevention. The current recommendation from the Ministry of Health in Brazil for HIV-positive children vaccination is the four-dose schedule (0, 1,6 and 12months) with a double dose. OBJECTIVES: Study the serologic response to a booster dose with the hepatitis B vaccine in HIV-infected children who had been previously vaccinated with three double doses but did not present protective titles. Study the relationship of CD4 levels and the viral load with protective titles at the time of the booster. Study the relationship between the time gap from the first vaccination to the first serologic evaluation and the presence of protective titles, as well as the relationship between the time gap from the third vaccine dose to the booster and the presence of protective titles. METHODOLOGY: The present research consists of a prospective descriptive study of a sample of 70 HIV-infected children out of a total of 187 children enrolled in a follow-up program at the Infectology sector of the Instituto da Criança (Childrens Institute HCFMUSP) from August 2005 through November 2006. First of all, the patients who met the admission criteria had their anti-HBs serologic titles tested. Then the ones whose anti-HBs serologic titles were lower than 10 mUI/mL received a vaccine booster (20 g). Those patients who received the booster had their serologic titles tested again between one and three months after that. RESULTS: It was found that most patients (50=71.4%) did not present anti-HBs serologic titles > 10 mUI/mL at the moment of the first laboratory evaluation. The average time gap between the third dose of the vaccine and the serologic testing of the patients who presented protective titles was of 53.8 months, while the average time in the group who lacked protective titles was of 74 months (p=0.007). The rate of no protective titles after the booster dose in those patients was 68%; on the other hand, only 32% presented protective serology after the booster. The studys data did not show a statistically significant relationship between CD4 levels and viral load with the response to the booster dose. CONCLUSIONS: The study of the time gap between the last dose of the first vaccination and the serology testing suggests that the protective titles (anti-HBs) tend to decrease with time. The serologic lack of response or the nonprotective titles response to hepatitis B vaccine prevailed in the study sample of HIV-infected children even after they received the booster double dose.
Morais, Eliane de Oliveira. "Vacinação de hepatite B intradermica em pacientes com falencia renal cronica : imunogenicidade e seguimento." [s.n.], 2007. http://repositorio.unicamp.br/jspui/handle/REPOSIP/310587.
Full textTese (doutorado) - Universidade Estadual de Campinas, Faculdade de Ciencias Medicas
Made available in DSpace on 2018-08-09T15:51:43Z (GMT). No. of bitstreams: 1 Morais_ElianedeOliveira_D.pdf: 3278461 bytes, checksum: abbd8e7c590c9cf33a356bf37a2a2616 (MD5) Previous issue date: 2007
Resumo: Pacientes renais crônicos (RC) em estágio terminal dialisados ou não apresentam menores taxas de soroconversão após vacina de hepatite B. O objetivo do estudo foi avaliar de forma prospectiva a imunogenicidade da vacina de hepatite B por via intradérmica (ID) em pacientes RC (fase dialítica e pré-dialítica) com idade maior ou igual a 18 anos, bem como o seguimento dos títulos de anticorpos por um período de 12 meses. Incluídos pacientes que nunca tinham sido vacinados para hepatite B(anti-Hbs
Doutorado
Clinica Medica
Doutor em Clínica Médica
Lara, Amanda Nazareth. "Avaliação de marcadores sorológicos de proteção e infecção pelo vírus da hepatite B em pessoas vivendo com HIV/Aids, vacinadas previamente para hepatite B." Universidade de São Paulo, 2017. http://www.teses.usp.br/teses/disponiveis/5/5134/tde-07082017-092803/.
Full textBACKGROUND: Hepatitis B Virus (HBV) infection is responsible for great part of chronic hepatic diseases worldwide. In people living with HIV (PLHIV), HBV infection has more risk of progressing to cirrhosis and hepatocarcinoma. Hepatitis B vaccine is important in the prevention of a potentially severe disease, particularly in PLHIV, since both viruses have the same routes of transmission and co-infection has greater morbidity. Immunocompetent individuals have a good humoral response after the first hepatitis B vaccine series and no recommendation is made regarding booster doses. PLHIV may have a poor hepatitis B vaccine response, when compared to immunocompetent and the duration of immunity in these patients is unknown. OBJECTIVES: General: Evaluate serological markers of infection and protection from HBV in PLHIV previously vaccinated for hepatitis B. Specific: Evaluate anti-HBs persistence in PLHIV previously vaccinated for HBV who responded to a primary vaccine series; evaluate response to revaccination for hepatitis B in patients who did not respond to first vaccine series; investigate serological markers of infection from HBV in PLHIV previously vaccinated for hepatitis B. METHODS: Observational retrospective study of a PLHIV cohort primarily vaccinated between 2001 and 2002 for hepatitis B. Serological markers of infection and protection from HBV were investigated in those patients who were still attending the HIV/AIDS Patient Care Extension Service at the Clinical Division of Infectious and Parasitic Diseases attached to Hospital das Clínicas at Faculdade de Medicina at Universidade de São Paulo between 2012 and 2014. RESULTS: A cohort of 121 PLHIV was analyzed for seroconversion and persistence of anti-HBs. The majority were female (54.5%) and mean age 50.1 years. From these patients, 58 (group 1) were initially responders to the first vaccine series (anti- HBs >=10 mIU/mL) and 63 (group 2) were non- responders. After a median period of 11 years, none of the patients had serologic evidence of HBV infection and 41/58 (70.7%) of the initially responders had maintained anti-HBs >=10 mIU/mL. Greater CD4+ cell counts and anti- HBs>= 100mIU/mL at the time of first vaccine series were associated with persistence of anti-HBs. During evaluation period, 35/63 (55.6%) of the initially non-responders (group 2) successfully seroconverted (anti-HBs >=10 mIU/mL) in response to one or more booster doses. Booster doses may be effective in PLHIV. Number of booster doses were associated to seroconversion. Seventy of the 121 patients did not receive any further booster doses of hepatitis B vaccine from the time of their seroconversion (anti-HBs >=10 mIU/mL) (group 3). After 10 years of the seroconversion, 54/70 (77,1%) of these individuals has maintained anti- HBs >= 10 mIU/mL. CONCLUSIONS: Evaluation of serological markers for HBV in PLHIV previously vaccinated for hepatitis B showed: strong persistence of anti-HBs after a period of 10 to 11 years; additional vaccine doses elicited humoral response in initially non-responders; there was no serologic evidence of HBV infection (HbsAg ou Anti-HBc) about 11 years after initial vaccination
Books on the topic "Hepatitis B cor"
United States. Occupational Safety and Health Administration. Enforcement procedures for the occupational exposure to Bloodborne Pathogens Standard, 29 CFR 1910.1030. Washington, D.C: U.S. Dept. of Labor, Assistant Secretary for Occupational Safety and Health, 1992.
Find full textProtocolo para estimar la mortalidad por cirrosis y por carcinoma hepatocelular atribuible a las hepatitis virales B y C. Pan American Health Organization, 2021. http://dx.doi.org/10.37774/9789275323762.
Full textSegurola, Carmelo Loinaz. Trasplante Hepático en Pacientes con Antigeno de Superficie Del Virus B de la Hepatitis: Estudio Clínico y Virológico. Universidad Complutense de Madrid, Servicio de Publicaciones, 2005.
Find full textPrevención de la transmisión maternoinfantil del virus de la hepatitis B. Directrices sobre la profilaxis con antivirales en el embarazo. Pan American Health Organization, 2022. http://dx.doi.org/10.37774/9789275324820.
Full textOrientaciones mundiales sobre los criterios y procesos para la validación de la eliminación de la transmisión maternoinfantil del VIH, la sífilis y el virus de la hepatitis B. Pan American Health Organization, 2022. http://dx.doi.org/10.37774/9789275325858.
Full textLourenço, Emerson Botelho, ed. Avanços científicos em medicina 2. Bookerfield Editora, 2021. http://dx.doi.org/10.53268/bkf21120200.
Full textBook chapters on the topic "Hepatitis B cor"
Marcelin, Jasmine Riviere, Lynda A. Szczech, and Stacey Rizza. "Glomerular Diseases Associated with HIV, Hepatitis B, and Hepatitis C Infections." In Core Concepts in Parenchymal Kidney Disease, 209–28. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-8166-9_13.
Full textYan, Yan, and Chantsalmaa Davgadorj. "Establishment of a Mouse Model of Chronic Hepatitis B Virus Infection and Purification of Hepatic Parenchymal and Non-Parenchymal Cells." In Hepatitis B [Working Title]. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.99939.
Full textMendes, Alice Silva, and France Keiko Nascimento Yoshioka. "CARACTERIZAÇÃO DAS BOLSAS DE SANGUE RETIDAS NOS HEMOCENTROS EM UM ESTADO NORDESTE BRASILEIRO." In A SAÚDE PÚBLICA EM CONTEXTO MULTIDISCIPLINAR. Literacia Cientifica Editora & Cursos, 2021. http://dx.doi.org/10.53524/lit.edt.978-65-995572-5-5/09.
Full textSantos, Joelma Carvalho, Liana Ribeiro Gouveia, Andrea Dória Batista, Izolda Maria Fernandes de Moura, and Michele Maria Gonçalves de Godoy. "IDENTIFICAÇÃO DE ALTERAÇÕES NA ATIVIDADE DAS ENZIMAS HEPÁTICAS EM PACIENTES COM INFECÇÃO CRÔNICA PELOS VÍRUS DA HEPATITE B OU C POR METABONÔMICA BASEADA EM RMN DE 1 H." In Avanços científicos em medicina 2, 124–39. Bookerfield Editora, 2021. http://dx.doi.org/10.53268/bkf21120209.
Full textConference papers on the topic "Hepatitis B cor"
Tomaz, Isabella Santos, GIOVANNA MATIAS DUARTE, CECILIA BRUNA DE ALMEIDA, and LETICIA CRISTINA CHAVES BANDEIRA. "IMUNOPROFILAXIA: PREVENÇÃO DAS HEPATITES VIRAIS." In II Congresso Brasileiro de Imunologia On-line. Revista Multidisciplinar em Saúde, 2022. http://dx.doi.org/10.51161/ii-conbrai/6034.
Full textSilva, Clarissa Gonçalves da, Marcia Santana da Silva, Fábia Lisboa de Souza, Lídia de Nazaré Pantoja, and Ana Lúcia Fontes Eppinghaus. "Perfil epidemiológico das hepatites B e C no município de Niterói (RJ) de 2011 a 2021." In XIII Congresso da Sociedade Brasileira de DST - IX Congresso Brasileiro de AIDS - IV Congresso Latino Americano de IST/HIV/AIDS. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/dst-2177-8264-202133p118.
Full textCarvalho, Igor de Oliveira, and Lara Cristina da Cunha Guimarães Silva. "Análise da cobertura vacinal de hepatite B em Goiás, sinais de alerta." In XIII Congresso da Sociedade Brasileira de DST - IX Congresso Brasileiro de AIDS - IV Congresso Latino Americano de IST/HIV/AIDS. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/dst-2177-8264-202133p303.
Full textSilva, Izabelly Virginia Pereira Jorge da, SAMIRA FERNANDES FREITAS, JOSÉ BENTO JÚNIOR DA SILVA, JOSIVÂNIA OLIVEIRA PEREIRA, and NAHENAND ROCHA ALVES FIRME. "REVISÃO BIBLIOGRÁFICA: IMUNOPATOLOGIA DA INFECÇÃO POR HEPATITE B." In II Congresso Brasileiro de Imunologia On-line. Revista Multidisciplinar em Saúde, 2022. http://dx.doi.org/10.51161/ii-conbrai/6766.
Full textGoes, Hilda Carla Azevedo, Ana Carolina Alves Correa, Bruno José Sarmento Botelho, Gabriel Dos Santos Pereira Neto, and Claudia Ribeiro Menezes. "ANÁLISE EPIDEMIOLÓGICA DE HEPATITE VIRAL NOTIFICADA NO ESTADO DO PARÁ NOS ANOS DE 2016 A 2018." In I Congresso Brasileiro de Doenças Infectocontagiosas On-line. Revista Multidisciplinar em Saúde, 2021. http://dx.doi.org/10.51161/rems/2145.
Full textSoares, Edina Joana, Gabrielle Muller Sarolli Dall´Igna, Josana Horvart Dranka, Luciana Osorio Cavalli, and Roberto Ferreira Oizumi. "Prevalência de vírus da imunodeficiência humana, sífilis, hepatites B e C em pessoas em situação de rua no município de Cascavel (PR)." In XIII Congresso da Sociedade Brasileira de DST - IX Congresso Brasileiro de AIDS - IV Congresso Latino Americano de IST/HIV/AIDS. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/dst-2177-8264-202133p139.
Full textBarros, Dyovana Raissa de Souza, Maralucia Souza De Jesus, Luis Gustavo Sarges Da Silva, Taina Alves Dos Santos Beserra, and Helton Camilo Teixeira. "PREVENÇÃO E DIAGNOSTICO PRECOCE DA HEPATITE B NA GESTAÇÃO PELO ENFERMEIRO DURANTE O PRE-NATAL DE BAIXO RISCO." In II Congresso Brasileiro de Saúde On-line. Revista Multidisciplinar em Saúde, 2021. http://dx.doi.org/10.51161/rems/1511.
Full textMoura, Rayane de Oliveira, Igor Alecrim Santiago, Jhonatan Soares De Lacerda, Rayane Gomes De Oliveira Da Silva E. Souza, and Elton Carlos De Almeida. "ÍNDICE COMPOSTO DAS HEPATITES VIRAIS B E DELTA NA REGIÃO NORTE DO BRASIL." In II Congresso Nacional Multidisciplinar em Enfermagem On-line. Revista Multidisciplinar em Saúde, 2021. http://dx.doi.org/10.51161/rems/2553.
Full textSECCHI, Vanessa Loss, Maria Eduarda Nehring HELDT, Maria Luiza Corá FETTER, and Viviane MENDONÇA. "CARACTERÍSTICAS DEMOGRÁFICAS DOS CASOS DE HEPATITE VIRAL NOTIFICADOS DE 2017 A 2019 NO ESTADO DO RIO GRANDE DO SUL." In Semana Online Científica de Medicina. CONGRESSE.ME, 2021. http://dx.doi.org/10.54265/qvzk9174.
Full textQueiroz, Maisa Leitão de, Jéssica Karen de Oliveira Maia, Nikaelly Pinheiro Mota, Livia de Paulo Pereira, Vanessa da Frota Santos, and Marli Teresinha Gimeniz Galvão. "Hepatites virais: série temporal de casos de uma maternidade pública em Fortaleza, Ceará." In XIII Congresso da Sociedade Brasileira de DST - IX Congresso Brasileiro de AIDS - IV Congresso Latino Americano de IST/HIV/AIDS. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/dst-2177-8264-202133p009.
Full text